SCHEMBL25300658

SCHEMBL25300658

Cc1nn(CCc2ccccc2)c2c1cc(O)c1ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.42
▸ SRC P12931 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ PRKACG P22612 1/20 0.41
▸ PRKACB P22694 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GRN P28799 1/20 0.40
▸ SORT1 Q99523 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GFER P55789 1/20 0.39
▸ CASR P41180 7/20 0.39
▸ GLS O94925 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ BCL2 P10415 1/20 0.36
▸ BCL2L1 Q07817 1/20 0.36
▸ MCL1 Q07820 1/20 0.36
▸ BCL2A1 Q16548 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404961 1.00 MAPK1 (0.42) MAPK1SRCPRKACAPRKACGPRKACB
SCHEMBL25296141 0.93 SRC (0.46) MAPK1SRCPRKACAPRKACGPRKACB
SCHEMBL29402010 0.93 SRC (0.46) MAPK1SRCPRKACAPRKACGPRKACB
SCHEMBL29404923 0.92 GFER (0.38) MAPK1SRCPRKACAPRKACGPRKACB
SCHEMBL25255812 0.92 GFER (0.38) MAPK1SRCPRKACAPRKACGPRKACB
SCHEMBL25301767 0.90 KMT2A (0.41) KMT2AGFERCASRGLS
SCHEMBL29405442 0.86 L3MBTL1 (0.52) MAPK1SRCL3MBTL1MEN1KMT2A
SCHEMBL25257835 0.86 L3MBTL1 (0.52) MAPK1SRCL3MBTL1MEN1KMT2A
SCHEMBL25299914 0.82 ATM (0.44) L3MBTL1MEN1KMT2A
SCHEMBL29403919 0.82 ATM (0.44) L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 — — US disclosed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 — — US disclosed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 — — EP disclosed
CN-115956071-A Imidazoquinoline or benzindazolone compounds and intermediates for their preparation LMITO药业株式会社 2023-04-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME NQO1, NFE2L2, KEAP1 MAPK1 733/4885SRC 4011/4885PRKACA 2728/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 MAPK1 900/4885SRC 3910/4885PRKACA 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback